(Q39084242)

English

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

scientific article published on 9 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

author name string

Elizabeth R Plimack

1

1 reference

Europe PubMed Central

8 September 2017

Joaquim Bellmunt

2

1 reference

Europe PubMed Central

8 September 2017

Shilpa Gupta

3

1 reference

Europe PubMed Central

8 September 2017

Raanan Berger

4

1 reference

Europe PubMed Central

8 September 2017

Laura Q M Chow

5

1 reference

Europe PubMed Central

8 September 2017

Jonathan Juco

6

1 reference

Europe PubMed Central

8 September 2017

Jared Lunceford

7

1 reference

Europe PubMed Central

8 September 2017

Sanatan Saraf

8

1 reference

Europe PubMed Central

8 September 2017

Rodolfo F Perini

9

1 reference

Europe PubMed Central

8 September 2017

Peter H O'Donnell

10

1 reference

Europe PubMed Central

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 January 2017

1 reference

Europe PubMed Central

8 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

8 September 2017

18

1 reference

Europe PubMed Central

8 September 2017

2

1 reference

Europe PubMed Central

8 September 2017

212-220

1 reference

Europe PubMed Central

8 September 2017

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging concepts of T cell metabolism as a target of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930007-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30007-4

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39084242&oldid=1806933329"